INVA Innoviva, Inc.

-0.14  -1%
Previous Close 12.23
Open 12.25
Price To book 0.00
Market Cap 1.32B
Shares 109,354,000
Volume 664,632
Short Ratio 16.11
Av. Daily Volume 1,499,540

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Filing announced November 21, 2016. PDUFA estimate September 21, 2017.
Chronic obstructive pulmonary disease (COPD)
Phase 3 study completion due 2018.
Closed Triple

Latest News

  1. Seth Klarman Sells Innoviva Days After Activist Stakeholder Defeat
  2. Innoviva to Participate in Bank of America Merrill Lynch Healthcare Conference on May 17
  3. Relvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with Their Usual Care
  4. Edited Transcript of INVA earnings conference call or presentation 27-Apr-17 9:00pm GMT
  5. Innoviva misses 1Q profit forecasts
  6. Innoviva Reports First Quarter 2017 Financial Results
  7. Investor Network: Innoviva, Inc. to Host Earnings Call
  8. Sarissa Asks Innoviva Directors To Explain Continued Director Over-Compensation Despite Promises To Cut Costs
  9. Innoviva, Inc. – Value Analysis (NASDAQ:INVA) : April 24, 2017
  10. Sarissa Takes Innoviva to Court Over Busted Agreement
  11. Innoviva, Inc. breached its 50 day moving average in a Bearish Manner : INVA-US : April 21, 2017
  12. Innoviva to Report First Quarter Financial Results on April 27 at 5:00 p.m. EDT
  13. Overwhelming Majority Of Non-GSK Shareholders Support Sarissa Capital And Not Innoviva Board And Management
  14. Sarissa Lawsuit Likely After Innoviva Claims Win Over Dissidents
  15. Here's Why Innoviva Inc. Lost 10% Today
  16. Innoviva Says It Fends Off Sarissa Dissidents
  17. Innoviva Announces Preliminary Results of Annual Meeting
  18. Innoviva director vote drama hands last-minute loss to Sarissa
  19. Innoviva prevails in proxy fight against activist Sarissa-source
  20. Activist Sarissa says Innoviva backed out of proxy settlement deal